M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501)

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic profile of M9466 with and without tuvusertib or an ARPi and early signs of clinical activity of M9466 with tuvusertib in participants with advanced solid tumors. Study details include: Study/Treatment Duration: Participants will be treated until disease progression, death, discontinuation, or End of Study. Visit Frequency: Every week in the first 2 cycles, followed by every 3 weeks in the subsequent cycles. An End of Treatment Visit and Safety Follow-up/Discontinuation Visit are scheduled after the treatment period.

NCT Number	NCT06421935
Lead Sponsor	EMD Serono Research & Development Institute, Inc. Collaborators: Merck KGaA, Darmstadt, Germany
Conditions	Advanced Solid Tumor
Enrollment	60 participants
Start Date	2024-08-07
Primary Completion	2027-02-22 (estimated)
Study Completion	2027-02-22 (estimated)
Updated on ClinicalTrials.gov	2026-06-30